Top

Published in:

Open Access 01-11-2018 | Review Article

Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes

Authors: Xia Wang, Peilin Zheng, Gan Huang, Lin Yang, Zhiguang Zhou

Published in: Clinical and Experimental Medicine | Issue 4/2018

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors constitute a novel class of anti-diabetic agents confirmed to improve glycemic control and preserve β-cell function in type 2 diabetes. Three major large-scale studies, EXAMINE, SAVOR-TIMI 53, and TECOS, have confirmed the cardiovascular safety profile of DPP-4 inhibitors. Based on these results, DPP-4 inhibitors have gained widespread use in type 2 diabetes treatment. It is currently unknown, however, whether DPP-4 inhibitors have similar therapeutic efficacy against autoimmune diabetes. Several in vitro and in vivo studies have addressed this issue, but the results remain controversial. In this review, we summarize experimental findings and preliminary clinical trial results, and identify potentially effective immune modulation targets of DPP-4 inhibitors for autoimmune diabetes.

Zhou Z, Xiang Y, Ji L, et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes. 2013;62(2):543–50.PubMedPubMedCentral

Andersson C, Kolmodin M, Ivarsson SA, et al. Islet cell antibodies (ICA) identify autoimmunity in children with new onset diabetes mellitus negative for other islet cell antibodies. Pediatr Diabetes. 2014;15(5):336–44.PubMed

Borg H, Fernlund P, Sundkvist G. Protein tyrosine phosphatase-like protein IA2-antibodies plus glutamic acid decarboxylase 65 antibodies (GADA) indicates autoimmunity as frequently as islet cell antibodies assay in children with recently diagnosed diabetes mellitus. Clin Chem. 1997;43(12):2358–63.PubMed

Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia. 2005;48(4):703–8.PubMed

Huang G, Wang X, Li Z, Li H, Li X, Zhou Z. Insulin autoantibody could help to screen latent autoimmune diabetes in adults in phenotypic type 2 diabetes mellitus in Chinese. Acta Diabetol. 2010;49(5):327–31.PubMed

Huang G, Xiang Y, Pan L, Li X, Luo S, Zhou Z. Zinc transporter 8 autoantibody (ZnT8A) could help differentiate latent autoimmune diabetes in adults (LADA) from phenotypic type 2 diabetes mellitus. Diabetes Metab Res Rev. 2013;29(5):363–8.PubMed

McLaughlin KA, Richardson CC, Ravishankar A, et al. Identification of tetraspanin-7 as a target of autoantibodies in type 1 diabetes. Diabetes. 2016;65(6):1690–8.PubMed

Walther D, Eugster A, Jergens S, et al. Tetraspanin 7 autoantibodies in type 1 diabetes. Diabetologia. 2016;59(9):1973–6.PubMed

Tiittanen M, Huupponen JT, Knip M, Vaarala O. Insulin treatment in patients with type 1 diabetes induces upregulation of regulatory T-cell markers in peripheral blood mononuclear cells stimulated with insulin in vitro. Diabetes. 2006;55(12):3446–54.PubMed

10.

Guglielmi C, Palermo A, Pozzilli P. Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy. Diabetes Metab Res Rev. 2012;28(Suppl 2):40–6.PubMed

11.

Yang Z, Zhou Z, Li X, Huang G, Lin J. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Res Clin Pract. 2009;83(1):54–60.PubMed

12.

Frandsen CS, Dejgaard TF, Madsbad S. Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. Lancet Diabetes Endocrinol. 2016;4(9):766–80.PubMed

13.

White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.PubMed

14.

Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.PubMed

15.

Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42.PubMed

16.

Kim SC, Glynn RJ, Liu J, Everett BM, Goldfine AB. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol. 2014;51(6):1015–23.PubMedPubMedCentral

17.

Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(2):112–20.PubMed

18.

Xia C, Goud A, D’Souza J, et al. DPP4 inhibitors and cardiovascular outcomes: safety on heart failure. Heart Fail Rev. 2017;22(3):299–304.PubMedPubMedCentral

19.

Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71(11):1441–67.PubMed

20.

Radenkovic M, Silver C, Arvastsson J, et al. Altered regulatory T cell phenotype in latent autoimmune diabetes of the adults (LADA). Clin Exp Immunol. 2016;186(1):46–56.PubMedPubMedCentral

21.

Deng C, Xiang Y, Tan T, et al. Altered peripheral B-lymphocyte subsets in type 1 diabetes and latent autoimmune diabetes in adults. Diabetes Care. 2016;39(3):434–40.PubMed

22.

Akesson C, Uvebrant K, Oderup C, et al. Altered natural killer (NK) cell frequency and phenotype in latent autoimmune diabetes in adults (LADA) prior to insulin deficiency. Clin Exp Immunol. 2010;161(1):48–56.PubMedPubMedCentral

23.

Nieminen JK, Vakkila J, Salo HM, et al. Altered phenotype of peripheral blood dendritic cells in pediatric type 1 diabetes. Diabetes Care. 2012;35(11):2303–10.PubMedPubMedCentral

24.

Pinheiro MM, Stoppa CL, Valduga CJ, et al. Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro. Eur J Pharm Sci. 2017;100:17–24.PubMed

25.

Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond). 2005;108(4):277–92.

26.

Zhao Y, Yang L, Zhou Z. Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs. J Diabetes. 2014;6(1):21–9.PubMed

27.

Zhong J, Gong Q, Goud A, Srinivasamaharaj S, Rajagopalan S. Recent advances in dipeptidyl-peptidase-4 inhibition therapy: lessons from the bench and clinical trials. J Diabetes Res. 2015;2015:606031.PubMedPubMedCentral

28.

Scheen AJ. A review of gliptins for 2014. Expert Opin Pharmacother. 2015;16(1):43–62.PubMed

29.

Astry B, Venkatesha SH, Moudgil KD. Involvement of the IL-23/IL-17 axis and the Th17/Treg balance in the pathogenesis and control of autoimmune arthritis. Cytokine. 2015;74(1):54–61.PubMedPubMedCentral

30.

Stechova K, Bohmova K, Vrabelova Z, et al. High T-helper-1 cytokines but low T-helper-3 cytokines, inflammatory cytokines and chemokines in children with high risk of developing type 1 diabetes. Diabetes Metab Res Rev. 2007;23(6):462–71.PubMed

31.

Hull CM, Peakman M, Tree TIM. Regulatory T cell dysfunction in type 1 diabetes: what’s broken and how can we fix it? Diabetologia. 2017;60(10):1839–50.PubMedPubMedCentral

32.

Qiao YC, Shen J, Hong XZ, et al. Changes of regulatory T cells, transforming growth factor-beta and interleukin-10 in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. Clin Immunol. 2016;170:61–9.PubMed

33.

Ryba-Stanislawowska M, Rybarczyk-Kapturska K, Mysliwiec M, Mysliwska J. Elevated levels of serum IL-12 and IL-18 are associated with lower frequencies of CD4(+)CD25 (high)FOXP3 (+) regulatory t cells in young patients with type 1 diabetes. Inflammation. 2014;37(5):1513–20.PubMed

34.

Bin Dhuban K, Kornete M, Edward SM, Piccirillo CA. Functional dynamics of Foxp3(+) regulatory T cells in mice and humans. Immunol Rev. 2014;259(1):140–58.PubMed

35.

Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes. 2005;54(1):92–9.PubMed

36.

Yang Z, Zhou Z, Huang G, et al. The CD4(+) regulatory T-cells is decreased in adults with latent autoimmune diabetes. Diabetes Res Clin Pract. 2007;76(1):126–31.PubMed

37.

Li Y, Zhao M, Hou C, et al. Abnormal DNA methylation in CD4 + T cells from people with latent autoimmune diabetes in adults. Diabetes Res Clin Pract. 2011;94(2):242–8.PubMed

38.

Cabrera SM, Rigby MR, Mirmira RG. Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med. 2012;12(10):1261–72.PubMedPubMedCentral

39.

Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, et al. Administration of CD4 + CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care. 2012;35(9):1817–20.PubMedPubMedCentral

40.

Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol. 2007;19(6):652–7.PubMedPubMedCentral

41.

Fores JP, Crisostomo LG, Orii NM, et al. Th17 pathway in recent-onset autoimmune diabetes. Cell Immunol. 2017;324:8–13.PubMed

42.

Kumar P, Subramaniyam G. Molecular underpinnings of Th17 immune-regulation and their implications in autoimmune diabetes. Cytokine. 2015;71(2):366–76.PubMed

43.

Shao S, He F, Yang Y, Yuan G, Zhang M, Yu X. Th17 cells in type 1 diabetes. Cell Immunol. 2012;280(1):16–21.PubMed

44.

Marwaha AK, Crome SQ, Panagiotopoulos C, et al. Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol. 2010;185(7):3814–8.PubMed

45.

Ferraro A, Socci C, Stabilini A, et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes. 2011;60(11):2903–13.PubMedPubMedCentral

46.

Baharlou R, Ahmadi-Vasmehjani A, Davami MH, et al. Elevated levels of T-helper 17-associated cytokines in diabetes type i patients: indicators for following the course of disease. Immunol Invest. 2016;45(7):641–51.PubMed

47.

Reinert-Hartwall L, Honkanen J, Salo HM, et al. Th1/Th17 plasticity is a marker of advanced beta cell autoimmunity and impaired glucose tolerance in humans. J Immunol. 2015;194(1):68–75.PubMed

48.

Tsai S, Shameli A, Santamaria P. CD8 + T cells in type 1 diabetes. Adv Immunol. 2008;100:79–124.PubMed

49.

Hamel Y, Mauvais FX, Pham HP, et al. A unique CD8(+) T lymphocyte signature in pediatric type 1 diabetes. J Autoimmun. 2016;73:54–63.PubMed

50.

Mallone R, Martinuzzi E, Blancou P, et al. CD8 + T-cell responses identify beta-cell autoimmunity in human type 1 diabetes. Diabetes. 2007;56(3):613–21.PubMed

51.

Skowera A, Ladell K, McLaren JE, et al. beta-cell-specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure. Diabetes. 2015;64(3):916–25.PubMed

52.

Yi Z, Diz R, Martin AJ, et al. Long-term remission of diabetes in NOD mice is induced by nondepleting anti-CD4 and anti-CD8 antibodies. Diabetes. 2012;61(11):2871–80.PubMedPubMedCentral

53.

Scott GS, Fishman S, Khai Siew L, et al. Immunotargeting of insulin reactive CD8 T cells to prevent diabetes. J Autoimmun. 2010;35(4):390–7.PubMed

54.

Kim SJ, Nian C, McIntosh CH. Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4 + T-cell migration through incretin-dependent and -independent pathways. Diabetes. 2010;59(7):1739–50.PubMedPubMedCentral

55.

Yan S, Gessner R, Dietel C, Schmiedek U, Fan H. Enhanced ovalbumin-induced airway inflammation in CD26-/- mice. Eur J Immunol. 2012;42(2):533–40.PubMed

56.

Bengsch B, Seigel B, Flecken T, Wolanski J, Blum HE, Thimme R. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol. 2012;188(11):5438–47.PubMed

57.

Emamaullee JA, Davis J, Merani S, et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes. 2009;58(6):1302–11.PubMedPubMedCentral

58.

Honkanen J, Nieminen JK, Gao R, et al. IL-17 immunity in human type 1 diabetes. J Immunol. 2010;185(3):1959–67.PubMed

59.

Alonso N, Julian MT, Carrascal J, et al. Type 1 diabetes prevention in NOD mice by targeting DPPIV/CD26 is associated with changes in CD8(+)T effector memory subset. PLoS ONE. 2015;10(11):e0142186.PubMedPubMedCentral

60.

Pinheiro MM, Pinheiro FMM, Trabachin ML. Dipeptidyl peptidase-4 inhibitors (DPP-4i) combined with vitamin D3: an exploration to treat new-onset type 1 diabetes mellitus and latent autoimmune diabetes in adults in the future. Int Immunopharmacol. 2018;57:11–7.PubMed

61.

Shah P, Ardestani A, Dharmadhikari G, et al. The DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilization. J Clin Endocrinol Metab. 2013;98(7):E1163–72.PubMed

62.

Abbasi F, Amiri P, Sayahpour FA, et al. TGF-beta and IL-23 gene expression in unstimulated PBMCs of patients with diabetes. Endocrine. 2012;41(3):430–4.PubMed

63.

Cao H, Lu J, Du J, et al. TAK1 inhibition prevents the development of autoimmune diabetes in NOD mice. Sci Rep. 2015;5:14593.PubMedPubMedCentral

64.

Olivieri A, De Angelis S, Dionisi S, et al. Serum transforming growth factor beta1 during diabetes development in non-obese diabetic mice and humans. Clin Exp Immunol. 2010;162(3):407–14.PubMedPubMedCentral

65.

Tian L, Gao J, Hao J, et al. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology. 2010;151(7):3049–60.PubMed

66.

Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care. 2010;33(7):1607–9.PubMedPubMedCentral

67.

Takashima S, Fujita H, Fujishima H, et al. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. Kidney Int. 2016;90(4):783–96.PubMed

68.

Reinhold D, Hemmer B, Gran B, et al. Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4 + T cell clones. J Neuroimmunol. 1998;87(1–2):203–9.PubMed

69.

Ding L, Gysemans CA, Stange G, et al. Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice. PLoS ONE. 2014;9(9):e107935.PubMedPubMedCentral

70.

Schurmann C, Linke A, Engelmann-Pilger K, et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. J Pharmacol Exp Ther. 2012;342(1):71–80.PubMed

71.

Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 2011;60(4):1246–57.PubMedPubMedCentral

72.

Ervinna N, Mita T, Yasunari E, et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology. 2013;154(3):1260–70.PubMed

73.

Leung M, Leung DY, Wong VW. Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: a pilot study. Diab Vasc Dis Res. 2016;13(3):236–43.PubMed

74.

Sato A, Suzuki S, Watanabe S, et al. DPP4 inhibition ameliorates cardiac function by blocking the cleavage of HMGB1 in diabetic mice after myocardial infarction. Int Heart J. 2017;58(5):778–86.PubMed

75.

Sauve M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010;59(4):1063–73.PubMedPubMedCentral

76.

Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011;124(21):2338–49.PubMedPubMedCentral

77.

Satoh K. Dipeptidyl peptidase-4 inhibitors–emerging player for vascular protection. Circ J. 2013;77(5):1156–7.PubMed

78.

Sameshima A, Wada T, Ito T, et al. Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity. J Endocrinol. 2015;227(1):25–36.PubMed

79.

Conarello SL, Li Z, Ronan J, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci U S A. 2003;100(11):6825–30.PubMedPubMedCentral

80.

Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55(6):1695–704.PubMed

81.

Cho JM, Jang HW, Cheon H, et al. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing beta-cell replication and neogenesis. Diabetes Res Clin Pract. 2011;91(1):72–9.PubMed

82.

D’Alessio DA, Denney AM, Hermiller LM, et al. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(1):81–8.PubMed

83.

Utzschneider KM, Tong J, Montgomery B, et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care. 2008;31(1):108–13.PubMed

84.

Zhao Y, Yang L, Wang X, Zhou Z. The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes. Diabetes Metab Res Rev. 2014;30(8):646–53.PubMed

85.

Kim SJ, Nian C, Doudet DJ, McIntosh CH. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes. 2009;58(3):641–51.PubMedPubMedCentral

86.

Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves beta-cell mass in non-obese diabetic mice. J Endocrinol. 2012;214(3):381–7.PubMed

87.

Suarez-Pinzon WL, Cembrowski GS, Rabinovitch A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia. 2009;52(8):1680–2.PubMed

88.

Suarez-Pinzon WL, Rabinovitch A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces beta-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice. Cell Transplant. 2011;20(9):1343–9.PubMed

89.

Kim DH, Lee JC, Lee MK, Kim KW, Lee MS. Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition. Diabetologia. 2012;55(12):3308–17.PubMed

90.

Liang J, Leung KK, Lam SY, Leung PS. Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells. Diabetes Obes Metab. 2012;14(9):842–51.PubMed

91.

Cabrera SM, Colvin SC, Tersey SA, Maier B, Nadler JL, Mirmira RG. Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes. Clin Exp Immunol. 2013;172(3):375–82.PubMedPubMedCentral

92.

Pinheiro MM, Pinheiro FM, Torres MA. Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3. Endocrinol Diabetes Metab Case Rep. 2016;2016:16-0099.PubMedPubMedCentral

93.

Lima-Martinez MM, Guerra-Alcala E, Contreras M, Nastasi J, Noble JA, Polychronakos C. One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin. Endocrinol Diabetes Metab Case Rep. 2014;2014:140072.PubMedPubMedCentral

94.

Kandasamy N, Lennox G, Annamalai AK, Maguire G, Adler AI. Sitagliptin in glutamic acid decarboxylase antibody-positive diabetes mellitus. Endocr Pract. 2012;18(4):e65–8.PubMed

95.

Rapti E, Karras S, Grammatiki M, et al. Combined treatment with sitagliptin and vitamin D in a patient with latent autoimmune diabetes in adults. Endocrinol Diabetes Metab Case Rep. 2016;2016:150136.PubMedPubMedCentral

96.

Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med. 2011;28(10):1176–81.PubMed

97.

Garg SK, Moser EG, Bode BW, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013;19(1):19–28.PubMed

98.

Hari Kumar KV, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract. 2013;100(2):e55–8.PubMed

99.

Griffin KJ, Thompson PA, Gottschalk M, Kyllo JH, Rabinovitch A. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2014;2(9):710–8.PubMed

100.

Johansen OE, Boehm BO, Grill V, et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care. 2014;37(1):e11–2.PubMed

101.

Zhao Y, Yang L, Xiang Y, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab. 2014;99(5):E876–80.PubMed

102.

George PS, McCrimmon RJ. Saxagliptin co-therapy in C-peptide negative Type 1 diabetes does not improve counter-regulatory responses to hypoglycaemia. Diabet Med. 2016;33(9):1283–90.PubMed

103.

Buzzetti R, Pozzilli P, Frederich R, Iqbal N, Hirshberg B. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes Metab Res Rev. 2016;32(3):289–96.PubMed

104.

Guo H, Fang C, Huang Y, Pei Y, Chen L, Hu J. The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2016;121:184–91.PubMed

105.

Awata T, Shimada A, Maruyama T, et al. Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: an open-label randomized controlled pilot trial (SPAN-S). Diabetes Ther. 2017;8(5):1123–34.PubMedPubMedCentral

106.

Kim YG, Min SH, Hahn S, Oh TJ, Park KS, Cho YM. Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2016;116:86–95.PubMed

Title: Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes
Authors: Xia Wang
Peilin Zheng
Gan Huang
Lin Yang
Zhiguang Zhou
Publication date: 01-11-2018
Publisher: Springer International Publishing
Published in: Clinical and Experimental Medicine / Issue 4/2018
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-018-0519-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

TNF-R2 in tumor microenvironment as prognostic factor in epithelial ovarian cancer

Increased NGAL level associated with iron store in chronic kidney disease with anemia

Molecular biology as a tool for the treatment of cancer

Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients

MYLK promotes hepatocellular carcinoma progression through regulating cytoskeleton to enhance epithelial–mesenchymal transition

Cell adhesion molecules and plasminogen activator inhibitor type-1 (PAI-1) in patients with rheumatoid arthritis: influence of metabolic syndrome

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page